

Special Issue

Hematopoietic Stem Cell Transplantation: Current Status and Future Research

Message from the Guest Editor

Hematopoietic stem cell transplantation has been widely employed in the treatment of many haematological malignancies for many years. New advances have been achieved in the indications of this procedure, prevention of relapse post-transplant, donor selection and overall treatment strategy. The main indication of allogeneic transplantation remains acute leukaemia, either myeloid or lymphoblastic. In this field, the continuous advances in the biology allow better precision in the prognosis of an increasing number of patients. Thus, this issue requires a continuous update.

- Autologous transplantation has become accepted as the treatment for autoimmune diseases of the central nervous system, such as multiple sclerosis.
- Allogeneic transplant has been proposed as the treatment of severe sickle cell anaemia.
- A wide range of new antineoplastic agents have been introduced in the treatment of neoplastic diseases, and their use either before or after transplant may increase the efficacy and overall clinical results.
- CAR-T cells can also be obtained from lymphocytes derived from the donor, after transplant, and this opens the way for sequential treatment.
- and others.

Guest Editor

Dr. Giuseppe Milone

Department of Hematology, Bone Marrow Transplantation Unit, Azienda Ospedaliero Universitaria "Policlinico G. Rodolico—San Marco", 95124 Catania, Italy

Deadline for manuscript submissions

closed (30 November 2023)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/69804

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).